These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35020842)

  • 1. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
    Qian S; Xu J; Zhao S; Yang P; Yang C
    Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
    Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
    J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.
    Liu J; Zhao Z; Zou Y; Zhang M; Zhou Y; Li Y; Pang Z; Jin W
    Clin Rheumatol; 2015 May; 34(5):879-85. PubMed ID: 25564309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
    Yaseen MM; Abuharfeil NM; Darmani H
    Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FcRL4
    Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
    J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.
    Kobayashi M; Kawano S; Hatachi S; Kurimoto C; Okazaki T; Iwai Y; Honjo T; Tanaka Y; Minato N; Komori T; Maeda S; Kumagai S
    J Rheumatol; 2005 Nov; 32(11):2156-63. PubMed ID: 16265694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-36α axis is modulated in patients with primary Sjögren's syndrome.
    Ciccia F; Accardo-Palumbo A; Alessandro R; Alessandri C; Priori R; Guggino G; Raimondo S; Carubbi F; Valesini G; Giacomelli R; Rizzo A; Triolo G
    Clin Exp Immunol; 2015 Aug; 181(2):230-8. PubMed ID: 25902739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
    Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
    Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren's syndrome to facilitate their concerted migration.
    Blokland SLM; Kislat A; Homey B; Smithson GM; Kruize AA; Radstake TRDJ; van Roon JAG
    Scand J Immunol; 2020 Mar; 91(3):e12852. PubMed ID: 31733111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
    Xiao M; Duhem C; Chammout A; Berchem G; Janji B
    J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
    Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
    Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.